Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Abbisko Cayman Limited
  6. News
  7. Summary
    2256   KYG0028A1085

ABBISKO CAYMAN LIMITED

(2256)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abbisko Unit Doses First Patient in China Phase II Trial of Urothelial Cancer Therapy

12/01/2021 | 07:57pm EST


ę MT Newswires 2021
All news about ABBISKO CAYMAN LIMITED
01/17Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Devel..
PR
2021Abbisko Unit Doses First Patient in China Clinical Study of Rare Tumor Disease Therapy
MT
2021US Biotech Firm Sirnaomics Passes Hong Kong Listing Hearing
MT
2021Abbisko Unit Doses First Patient in China Phase II Trial of Urothelial Cancer Therapy
MT
2021Abbisko Therapeutics Doses First Patient in Giant Tumor Drug Trial in China; Shares Ral..
MT
2021Abbisko Therapeutics Co., Ltd. Announces Dosing of First Patient in the Phase I Clinica..
CI
2021Abbisko's Underwriters Partially Exercise Over-Allotment Option; Shares Slump 4%
MT
2021Abbisko Partner Completes Patient Enrollment for Phase 3 Study of Immunodeficiency Diso..
MT
2021ABBISKO CAYMAN : Therapeutics Gets FDA Nod to Start US Clinical Trial of Solid Tumor Drug
MT
2021ABBISKO CAYMAN : Wins Approval for Phase II Clinical Trial in China of Carcinoma Combinati..
MT
More news
Financials
Sales 2021 7,33 M 1,16 M 1,16 M
Net income 2021 -1 963 M -310 M -310 M
Net cash 2021 1 970 M 311 M 311 M
P/E ratio 2021 -3,51x
Yield 2021 -
Capitalization 5 621 M 721 M 886 M
EV / Sales 2021 498x
EV / Sales 2022 2 605x
Nbr of Employees 144
Free-Float -
Chart ABBISKO CAYMAN LIMITED
Duration : Period :
Abbisko Cayman Limited Technical Analysis Chart | 2256 | KYG0028A1085 | MarketScreener
Technical analysis trends ABBISKO CAYMAN LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,00 CNY
Average target price 13,61 CNY
Spread / Average Target 70,1%
EPS Revisions
Managers and Directors
Yao Chang Xu Chairman & Chief Executive Officer
Richard Yeh CFO, Executive Director & Head-Operations
Jing Ji Chief Medical Officer
Piao Yang Sun Independent Non-Executive Director
Hong Bin Sun Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ABBISKO CAYMAN LIMITED-12.09%704
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044